ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable

ARK Genomic Revolution ETF remains a buy as its valuation improves and technical support emerges after a 15% correction from July highs. ARKG’s portfolio is concentrated in small- and mid-cap biotech, with top 10 holdings comprising 59% and a long-term EPS growth rate now at 10.7%. Despite weak seasonality and high volatility, ARKG’s rising 200-day moving average and strong support at $34–$35 provide a favorable risk-reward setup. Regulatory reforms, risk-on sentiment, and stable or falling rates are key drivers for ARKG, whose high-beta profile rewards volatility-tolerant investors.

The Healthcare sector, along with Financials, notched a 52-week high amid the tech wreck on Tuesday, July 28. On Fed Decision Eve, there was certainly optimism among value stocks, while the AI and chip trade was under significant pressure. Toss in fresh